Novel mechanism of vasodilation in inflammatory bowel disease

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 25, Issue 11, 2005, Pages 2355-2361

  Hatoum, Ossama A ^a   Gauthier, Kathryn M ^a   Binion, David G ^a   Miura, Hiroto ^a   Telford, Gordon ^a   Otterson, Mary F ^a   Campbell, William B ^a   Gutterman, David D ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Cyclooxygenase; Inflammatory bowel disease; Microcirculation; Prostaglandin; Vasodilation

Indexed keywords

3 BENZYL 5 (6 CARBOXYHEXYL) 1 (2 CYCLOHEXYL 2 HYDROXYETHYLAMINO)HYDANTOIN; ACETYLCHOLINE; ARACHIDONIC ACID; ENDOTHELIAL DERIVED HYPERPOLARIZING FACTOR; ICOSANOID; INDOMETACIN; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN D2; PROSTAGLANDIN D2 RECEPTOR ANTAGONIST; PROSTAGLANDIN RECEPTOR BLOCKING AGENT; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG; VASODILATOR AGENT;

ADULT; ARTERIOLE; ARTERY CONSTRICTION; ARTERY ENDOTHELIUM; ARTICLE; BLOOD FLOW; CONTROLLED STUDY; ENTERITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; INTESTINE RESECTION; MALE; MICROCIRCULATION; MICROSCOPY; PRIORITY JOURNAL; VASODILATATION; VASOMOTOR REFLEX; VIDEORECORDING;

ACETYLCHOLINE; ADULT; AGED; ARACHIDONIC ACID; ARTERIOLES; BIOLOGICAL FACTORS; CARBON RADIOISOTOPES; CYCLOOXYGENASE INHIBITORS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; INDOMETHACIN; INFLAMMATORY BOWEL DISEASES; MALE; MICROSCOPY, VIDEO; MIDDLE AGED; NITRIC OXIDE; PROSTAGLANDIN D2; REACTIVE OXYGEN SPECIES; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; VASODILATION; VASODILATOR AGENTS;

EID: 27644598991     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.0000184757.50141.8d     Document Type: Article

References (34)

1. Terata K, Miura H, Liu Y, Loberiza F, Gutterman DD. Human coronary arteriolar dilation to adrenomedullin; role of nitric oxide and K(+) channels. Am J Physiol Heart Circ Physiol. 2000;279:H2620-H2626.
2. Cox DA, Vita JA, Treasure CB, Fish RD, Alexander RW, Ganz P, Selwyn AP. Atherosclerosis impairs flow-mediated dilation of coronary arteries in humans. Circulation. 1989;80:458-465.
3. Egashira K, Inou T, Hirooka Y, Yamada A, Urabe Y, Takeshita A. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med. 1993;328:1659-1664.
4. Hatoum OA, Binion DG, Otterson MF, Gutterman DD. Acquired microvascular dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. Gastroenterology. 2003;125:58-69.
5. Pober JS, Cotran RS. The role of endothelial cells in inflammation. Transplantation. 1990;50:537-544.
6. Miura H, Liu Y, Gutterman DD. Human coronary arteriolar dilation to bradykinin depends on membrane hyperpolarization: contribution of nitric oxide and Ca2+-activated K+ channels. Circulation. 1999;99: 3132-3138.
7. Miura H, Wachtel RE, Liu Y, Loberiza FR, Jr., Saito T, Miura M, Gutterman DD. Flow-induced dilation of human coronary arterioles: important role of Ca(2+)-activated K(+) channels. Circulation. 2001; 103:1992-1998.
8. Liu Y, Terata K, Rusch NJ, Gutterman DD. High glucose impairs voltage-gated K(+) channel current in rat small coronary arteries. Circ Res. 2001;89:146-152.
9. Miura H, Gutterman DD. Human coronary arteriolar dilation to arachidonic acid depends on cytochrome P-450 monooxygenase and Ca2+-activated K+ channels. Circ Res. 1998;83:501-507.
10. Miller FJ Jr., Dellsperger KC, Gutterman DD. Pharmacologic activation of the human coronary microcirculation in vitro: endothelium-dependent dilation and differential responses to acetylcholine. Cardiovasc Res. 1998;38:744-750.
11. Stein O, Stein Y. Bovine aortic endothelial cells display macrophage-like properties towards acetylated 1251-labelled low density lipoprotein. Biochim Biophys Acta. 1980;620:631-635.
12. Rosolowsky M, Campbell WB. Role of PGI2 and epoxyeicosatrienoic acids in relaxation of bovine coronary arteries to arachidonic acid. Am J Physiol. 1993;264:H327-H335.
13. Gauthier KM, Deeter C, Krishna UM, Reddy YK, Bondlela M, Falck JR, Campbell WB. 14,15-Epoxyeicosa-5(Z)-enoic acid: a selective epoxyeicosatrienoic acid antagonist that inhibits endothelium-dependent hyperpolarization and relaxation in coronary arteries. Circ Res. 2002;90: 1028-1036.
14. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. Immunol Today. 1991;12:349-352.
15. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol. 1971;231:232-235.
16. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology. 1997;112:1000-1016.
17. Wallace JL, Chin BC. Inflammatory mediators in gastrointestinal defense and injury. Proc Soc Exp Biol Med. 1997;214:192-203.
18. Wallace JL, McKnight W, Miyasaka M, Tamatani T, Paulson J, Anderson DC, Granger DN, Kubes P. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. Am J Physiol. 1993;265: G993-G998.
19. Wallace JL, McKnight GW. Characterization of a simple animal model for nonsteroidal anti-inflammatory drug induced antral ulcer. Can J Physiol Pharmacol. 1993;71:447-452.
20. Robert A. Antisecretory, antiulcer, cytoprotective and diarrheogenic properties of prostaglandins. Adv Prostaglandin Thromboxane Res. 1976; 2:507-520.
21. Robert A, Schultz JR, Nezamis JE, Lancaster C. Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration. Gastroenterology. 1976;70:359-370.
22. Gould SR, Brash AR, Conolly ME. Increased prostaglandin production in ulcerative colitis. Lancet. 1977;2:98.
23. Harris DW, Smith PR, Swan CH. Determination of prostaglandin synthetase activity in rectal biopsy material and its significance in colonic disease. Gut. 1978;19:875-877.
24. Rampton DS, Sladen GE, Youlten LJ. Prostaglandins and ulcerative colitis. Gastroenterology. 1980;78:192-193.
25. Rampton DS, Sladen GE, Youlten LJ. Rectal mucosal prostaglandin E2 release and its relation to disease activity, electrical potential difference, and treatment in ulcerative colitis. Gut. 1980;21:591-596.
26. Kaufmann HJ, Taubin HL. Nonsteroidal anti-inflammatory drugs activate quiescent inflammatory bowel disease. Ann Intern Med. 1987;107: 513-516.
27. Reuter BK, Asfaha S, Buret A, Sharkey KA, Wallace JL. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. J Clin Invest. 1996;98:2076-2085.
28. Ajuebor MN, Singh A, Wallace JL. Cyclooxygenase-2-derived prostaglandin D(2) is an early anti-inflammatory signal in experimental colitis. Am J Physiol Gastrointest Liver Physiol. 2000;279:G238-G244.
29. Zamuner SR, Warner N, Buret AG, MacNaughton WK, Wallace JL. Cyclooxygenase 2 mediates post-inflammatory colonic secretory and barrier dysfunction. Gut. 2003;52:1714-1720.
30. Liu Y, Gutterman DD. The coronary circulation in diabetes: influence of reactive oxygen species on K+ channel-mediated vasodilation. Vascul Pharmacol. 2002;38:43-49.
31. Lamping KG, Nuno DW, Shesely EG, Maeda N, Faraci FM. Vasodilator mechanisms in the coronary circulation of endothelial nitric oxide synthase-deficient mice. Am J Physiol Heart Circ Physiol. 2000;279: H1906-H1912.
32. Sun D, Huang A, Smith CJ, Stackpole CJ, Connetta JA, Shesely EG, Koller A, Kaley G. Enhanced release of prostaglandins contributes to flow-induced arteriolar dilation in eNOS knockout mice. Circ Res. 1999; 85:288-293.
33. Miura H, Bosnjak JJ, Ning G, Saito T, Miura M, Gutterman DD. Role for hydrogen peroxide in flow-induced dilation of human coronary arterioles. Circ Res. 2003;92:e31-e40.
34. Bosnjak JJ, Terata K, Miura H, Sato A, Nicolosi AC, McDonald M, Manthei SA, Saito T, Hatoum OA, Gutterman DD. Mechanism of thrombin-induced vasodilation in human coronary arterioles. Am J Physiol Heart Circ Physiol. 2003;284:H1080-H1086.